Agilent, Seoul National University Hospital Announce Strategic Collaboration on Biomarker Research

Agilent Technologies (NYSE: A) and Seoul National University Hospital, one of Korea's top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers. “There are gaps in the medical industry that hamper the quality of care we can provide to patients,” said Prof. Byung-Hee Oh, president and CEO, Seoul National University Hospital. “One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases.” “Our hospital is pleased to collaborate with Agilent, the premier test and measurement company,